About the Event
Currently 30% of the time surgeons perform breast surgery they don’t achieve a complete resection which doubles the risk of recurrence for these patients.
The Lumicell Direct Visualization System includes an imaging agent, device, and software that work together assist surgeons to detect cancerous tissue in real time so they can remove it all the first time. In clinical trials with over 700 patients in sites that include Stanford, MD Anderson, Mass General, Duke, and Cleveland Clinic, surgeons using the Lumicell DVS have demonstrated the ability to remove residual cancer left behind thus enabled a more complete cancer resection for patients.
Lumicell has completed their clinical trials and is in the process of filing a PMA for the device. They expect FDA approval in Q4 2023 with commercial launch in the first quarter of 2024 for Breast Cancer. LUMISIGHT™ is designed to work with all solid tumor cancers making it a platform technology with the potential for expanded indications in the future.
Join our webinar with Lumicell CEO, Kevin Hershberger, to learn how their technology is lighting the way to better outcomes for breast cancer patients.